Home   Business   Article

Subscribe Now

Revolo Biotherapeutics completes clinical trial of ‘1104 for allergic disease





Great Shelford-based Revolo Biotherapeutics has completed its phase 2a clinical trial of an immune-resetting drug, known as ‘1104, for allergic disease.

The company expects top-line data from the study in the second quarter of the year.

Jonathan Rigby, Revolo’s CEO (63224768)
Jonathan Rigby, Revolo’s CEO (63224768)

Revolo, which has offices at Windsor House in Station Court, as well as a US base in New Orleans, is developing therapies to reset the immune system to enable the long-term remission of patients with autoimmune and allergic conditions.

CEO Jonathan Rigby said: “We are pleased to have reached this relevant milestone and look forward to receiving data from the study in the near future.

“Building on the promising pre-clinical data that has showcased ‘1104’s long-lasting and allergen-agnostic anti-inflammatory effects, we are excited by this clinical progress. We look forward to initiating a food allergy clinical study where there is a very large unmet need as a next step in the development of ‘1104.”

The randomised, double-blind, placebo-controlled, parallel-group study was designed to evaluate the safety and efficacy of ‘1104 in 60 patients with moderate to severe allergy.

Participants received six doses of either ‘1104 or a placebo over six visits within the 12-week period.

The investigational drug is a first-in-class peptide derived from a natural immune-regulatory protein called mTB Chaperonin 60.1 that is involved in resetting the immune system.

Revolo Bio has advanced ‘1104 through two Phase 2a trials: one in patients with eosinophilic esophagitis (EoE) and one in patients with allergen sensitivity, while exploring its potential for other allergic diseases.



This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies - Learn More